Navigation Links
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
Date:10/14/2009

which led to exclusions before study completion and unblinding). The Matrix study evaluated safety as assessed by adverse events, clinical laboratory measurements, vital signs, concomitant medications, physical exam findings and serum antibody concentrations to collagen and adenovector. Preliminary measures of efficacy included the incidence of complete wound closure by 12 weeks and the effect of Excellarate on healing rates as measured by the change of the ulcer radius during the 4-week period following Excellarate treatment. In addition, patients whose wounds were successfully closed are being followed for up to three additional months to further evaluate wound healing durability. Durability results will be reported at a later date.

Excellarate appeared to be both safe and well tolerated in human patients with diabetic neuropathy. There were no substantial differences observed with respect to adverse events, clinical laboratory results, physical exam findings or immunological antibody responses to collagen or the adenovector in patients receiving either one or two doses of Excellarate or collagen matrix, as compared to each other or to standard of care.

Collagen, an FDA approved medical device, is an important and required element of the Company's Gene Activated Matrix technology and was also included as a key comparator group in the Phase 2b study, as an independent collagen-only treatment arm. Based on preclinical animal data suggesting that collagen would not contribute substantially to wound healing, the study was expected to demonstrate that collagen administration would be equivalent to standard of care, and that these groups would collectively form a control group. However, based on a preliminary review of the top line data, collagen appears to contribute to the healing response in human diabetic patients. While the standard of care (SOC) control group in the Phase 2b study was too small to support statistical differentiation o
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers
2. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
3. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
4. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
5. Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index
6. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
7. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
8. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
9. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
10. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
11. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as part ... the latest and coolest technology products and services available to ... technology expert, conducted the review and shared with viewers how ... stuck with a low battery and no way to charge ... on a daily basis. Even when a person does have ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... 27, 2015 Hispanics develop alcoholic liver ... four and 12 years earlier than Whites/Caucasians or African ... Health System. , While previous research indicated that Hispanics ... the new study -- published online in the journal ... be the first to pinpoint racial and ethnic disparities ...
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
Breaking Medicine News(10 mins):Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... time , , TUESDAY, Jan. 15 (HealthDay News) -- Foodborne illness can ... different pathogens. Here is a rundown of the most common bacterial ... E. COLI 0157:H7 , There are many strains ... coli. Most are harmless, four or five can cause disease, and ...
... drinks containing live bacteria, have a tangible effect on the ... today (Tuesday 15 January) in the journal Molecular Systems Biology. ... at how probiotics change the biochemistry of bugs known as ... an important part in a persons metabolic makeup. Different people ...
... Integrated Solutions Help Dearborn County Hospital Better Serve ... Area with Heightened Productivity and Collaboration, ... Dearborn County Hospital,in southeast Indiana, efficient yet responsive ... patients and patient,families. To boost care levels even ...
... Postmenopausal women who take combined estrogen/progestin hormone-replacement ... fourfold increased risk of developing various forms of ... researchers at Fred Hutchinson Cancer Research Center., Previous ... combined hormone-therapy use was necessary to increase overall ...
... feedback feature promotes a more informed health care ... and regional studies,indicate that informed patients make better ... is launching a member feedback feature in,Spring 2008 ... to share,information with each other about their provider ...
... Rivers,Pharmaceuticals, LLC finalized acquisition of the hepatitis C ... ). Valeant is,receiving $91 million from Three Rivers ... growing portfolio is very exciting," said,Donald J. Kerrish, ... purchase is only a beginning for Three Rivers, ...
Cached Medicine News:Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 2Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 3Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 4Health News:Probiotics affect metabolism, says new study 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 3Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 4Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 5Health News:Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use 2Health News:Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options 2Health News:Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals 2
(Date:2/27/2015)... , Feb. 27, 2015  Following a bipartisan ... that moved H.R. 284, the Medicare DMEPOS Competitive ... Association for Homecare (AAHomecare) released a statement praising ... to pass the legislation. "Today,s mark-up ... House Ways and Means Committee is a critical ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 ... EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") ... lock-up (the "Lock-Up") 2,353,130 common shares of the Company ... subject to the Lock-Up. Of the Common Shares released ... immediately upon release from the Lock-Up while the remainder ...
(Date:2/27/2015)...   Synageva BioPharma Corp. (Synageva) (NASDAQ: ... therapeutic products for rare diseases, joins the National ... for Rare Diseases™ (EURORDIS™), The Global Genes Project™, ... Disease Day. On the last day ... other participants conduct special events to raise awareness ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... with investigators worldwide to develop new treatments for ... diverse forms of cancer - Plenary ... of patients with early-stage breast cancer, - Four oral sessions to feature ... study in renal cell ...
... Hispanics/Latinos, People ... with Diabetes and Obese Individuals, PARSIPPANY, N.J., ... presented at the American Society of,Hypertension,s Twenty- Third Annual ... powerful combination drug AZOR(TM),(amlodipine and olmesartan medoxomil) safely and ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism....
... offers patient monitoring products for hospital ... medium acuity monitoring. The Envoy patient ... The Enmove monitor offers a ... complement the Envoy. The Ensemble ...
... The Mayfield Triad Skull Clamp, compatible with ... visual indication of clamping force on all ... user with the possibility of adjusting the ... can easily be increased or decreased by ...
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
Medicine Products: